{"id":"arv-471-in-combination-with-palbociclib-ibrance","_chembl":null,"allNames":"arv-471 in combination with palbociclib (ibrance), arv-471 in combination with palbociclib (ibrance®)","_dailymed":null,"mechanism":{"target":"ESR1, CDK4/6","drugClass":"Estrogen receptor degrader, CDK4/6 inhibitor","explanation":"ARV-471 targets estrogen receptors, which are often overactive in breast cancer, reducing tumor cell proliferation. Palbociclib stops cancer cells from dividing by inhibiting CDK4/6 enzymes, enhancing the anti-tumor effect.","oneSentence":"ARV-471 binds to estrogen receptors in breast cancer cells, while palbociclib inhibits CDK4/6, together blocking tumor growth."},"_scrapedAt":"2026-03-28T04:11:36.916Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:58:26.810355+00:00","fieldsConflicting":0,"overallConfidence":0.95},"trialDetails":[{"nctId":"NCT04072952","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Arvinas Estrogen Receptor, Inc.","startDate":"2019-08-05","conditions":"Breast Cancer","enrollment":217},{"nctId":"NCT04606446","phase":"PHASE1","title":"Study of PF-07248144 in Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Pfizer","startDate":"2020-11-16","conditions":"Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer, Locally Advanced or Metastatic Non-small Cell Lung Cancer","enrollment":320}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"ARV-471 in combination with palbociclib (IBRANCE®)","genericName":"arv-471-in-combination-with-palbociclib-ibrance","companyName":"Pfizer Inc.","companyId":"pfizer","modality":"","firstApprovalDate":"","aiSummary":"","enrichmentLevel":5,"visitCount":4,"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:58:26.810355+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}